Aminopyrimidinyl compounds

1. A method for treating a disorder or condition selected from [inflammation, autoimmune disease, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthropathies,] systemic lupus erythematous, lupus nephritis, [arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoidosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease,] inflammatory bowel disease, Crohn's disease, ulcerative colitis, [nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis,] multiple sclerosis, [endometriosis, menstrual cramps, vaginitis, candidiasis, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis,] autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, [Alzheimer's disease, skin flushing, eczema,] psoriasis, and atopic dermatitis [and sunburn], comprising administering to the subject a therapeutically effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 3 -C 6 cycloalkyl, aryl, heteroaryl, aryl(C 1 -C 6 alkyl), CN, amino, alkylamino, dialkylamino, CF 3 , or hydroxyl;

A is selected from the group consisting of a bond, C═O, —SO 2 —, —(C═O)NR 0 —, and —(CR a R b ) q —, where R 0 is H or C 1 -C 4 alkyl, and R a and R b are independently hydrogen, deuterium, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, aryl, aryl(C 1 -C 6 alkyl), heteroaryl, (C 1 -C 6 alkyl)heteroaryl, heteroaryl(C 1 -C 6 alkyl), and heterocyclic(C 1 -C 6 alkyl);

A′ is selected from the group consisting of a bond, C═O, —SO 2 —, —(C═O)NR 0 ′, —NR 0 ′(C═O)—, and —(CR a ′R b ′) q —, where R 0 ′ is H or C 1 -C 4 alkyl, and R a ′ and R b ′ are independently hydrogen, deuterium, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, aryl, aryl(C 1 -C 6 alkyl), heteroaryl, (C 1 -C 6 alkyl)heteroaryl, heteroaryl(C 1 -C 6 alkyl), and heterocyclic(C 1 -C 6 alkyl);

Z is —(CH 2 ) h — or a bond, where one or more methylene units are optionally substituted by one or more C 1 -C 3 alkyl, CN, OH, methoxy, or halo, and where said alkyl may be substituted by one or more fluorine atoms;

R 1 and R 1 ′ are independently selected from the group consisting of hydrogen, deuterium, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, aryl, heteroaryl, aryl(C 1 -C 6 alkyl), CN, amino, alkylamino, dialkylamino, alkoxy, heteroaryl(C 1 -C 6 alkyl), and heterocyclic(C 1 -C 6 alkyl), wherein said alkyl, aryl, cycloalkyl, heterocyclic, or heteroaryl is further optionally substituted with one or more substituents selected from the group consisting of C 1 -C 6 alkyl, halo, CN, hydroxy, methoxy, amino, C 1 -C 4 alkyl amino, di(C 1 -C 4 alkyl)amino, CF 3 , —SO 2 —(C 1 -C 6 alkyl), and C 3 -C 6 cycloalkyl;

R 2 is selected from the group consisting of hydrogen, deuterium, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo, and cyano, where said alkyl may be substituted by one or more fluorine atoms;

R 3 is selected from the group consisting of hydrogen, deuterium, and amino;

R 4 is monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl wherein said aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C 1 -C 6 alkyl, heterocycloalkyl, halo, CN, hydroxy, —CO 2 H, C 1 -C 6 alkoxy, amino, —N(C 1 -C 6 alkyl)(CO)(C 1 -C 6 alkyl), —NH(CO)(C 1 -C 6 alkyl), —(CO)NH 2 , —(CO)NH(C 1 -C 6 alkyl), —(CO)N(C 1 -C 6 alkyl) 2 , —(C 1 -C 6 alkyl)amino, —N(C 1 -C 6 alkyl) 2 , —SO 2 —(C 1 -C 6 alkyl), —(SO)NH 2 , and C 3 -C 6 cycloalkyl, where said alkyl, cycloalkyl, alkoxy, or heterocycloalkyl may be substituted by one or more C 1 -C 6 alkyl, halo, CN, OH, alkoxy, amino, —CO 2 H, —(CO)NH 2 , —(CO)NH(C 1 -C 6 alkyl), or —(CO)N(C 1 -C 6 alkyl) 2 , and where said alkyl may be further substituted by one or more fluorine atoms;

R 5 is independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and hydroxyl;

h is 1, 2 or 3; j and k are independently 0, 1, 2, or 3; m and n are independently 0, 1 or 2; and, q is 0, 1 or 2; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.

2. The method of claim 1 wherein the compound is selected from the group consisting of:

4-({4-[8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-5-fluoropyrimidin-2-yl}amino)-N-ethylbenzamide;

N-ethyl-4-({5-fluoro-4-[8-(trifluoroacetyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-2-methylbenzamide;

(1R,5S)-3-(2-{[5-methyl-6-(methylcarbamoyl)pyridin-3-yl]amino}pyrimidin-4-yl)-N-(2,2,2-trifluoroethyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

(1R,5S)-N-(cyanomethyl)-3-(2-{[5-methyl-6-(methylcarbamoyl)pyridin-3-yl]amino}pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

5-({4-[(1R,5S)-8-{[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N,3-dimethylpyridine-2-carboxamide;

tert-butyl 3-(2-{[4-(ethylcarbamoyl)-3-methylphenyl]amino}-5-fluoropyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate;

5-({4-[(1R,5S)-8-{[(1R,2R)-2-cyanocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N,3-dimethylpyridine-2-carboxamide;

3-chloro-5-({4-[(1R,5S)-8-{[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N-methylpyridine-2-carboxamide;

N-(1-methyl-1H-pyrazol-4-yl)-4-[(1R,5S)-8-(1,2-thiazol-5-ylmethyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-amine;

[(1S)-2,2-difluorocyclopropyl]{(1R,5S)-3-[2-({6-[(2S)-1-hydroxypropan-2-yl]pyridin-3-yl}amino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

3-chloro-5-({4-[(1R,5S)-8-{[(1R,2R)-2-cyanocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N-methylpyridine-2-carboxamide;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-(2-{[5-fluoro-6-(hydroxymethyl)pyridin-3-yl]amino}pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-[(4-{(1R,5S)-8-[(2,2-difluorocyclopropyl)carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino]-3-methylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N,3-dimethylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-(2-{[5-methyl-6-(methylcarbamoyl)pyridin-3-yl]amino}pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1S)-2,2-difluorocyclopropyl]{(1R,5S)-3-[2-({6-[(2R)-1-hydroxypropan-2-yl]pyridin-3-yl}amino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

N-(1-methyl-1H-pyrazol-4-yl)-4-[(1R,5S)-8-(1,2-oxazol-5-ylmethyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-amine;

cyclopropyl{(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

5-({4-[(1R,5S)-8-{[(1R,2R)-2-cyanocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide;

[(1R)-2,2-difluorocyclopropyl]{(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

5-({4-[(1R,5S)-8-{[(1R)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide;

N-ethyl-4-({5-fluoro-4-[6-(2-fluoro-2-methylpropanoyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]pyrimidin-2-yl}amino)-2-methylbenzamide;

(1R)-2,2-difluoro-N-[(1 S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

N-ethyl-2-methyl-4-({4-[6-(trifluoroacetyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]pyrimidin-2-yl}amino)benzamide;

4-({4-[6-(2,2-difluoropropanoyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]pyrimidin-2-yl}amino)-N-ethylbenzamide;

4-({4-[6-(cyclopropylcarbonyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]pyrimidin-2-yl}amino)-N-ethyl-2-methylbenzamide;

N-{(1S,5R,6R)-3-[5-fluoro-2-({6-[(2R)-1-hydroxypropan-2-yl]pyridin-3-yl}amino)pyrimidin-4-yl]-6-methyl-3-azabicyclo[3.1.0]hex-1-yl}cyclopropanecarboxamide;

N-[(1S,5R,6R)-3-(2-{[5-chloro-6-(hydroxymethyl)pyridin-3-yl]amino}-5-fluoropyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide; and,

N-[(1S,5R,6R)-3-(5-fluoro-2-{[6-(2-hydroxyethyl)pyridin-3-yl]amino}pyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

or, a pharmaceutically acceptable salt thereof.